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Abstract: Treatment-failure gout (TFG) affects approximately 50,000 patients or about 1% 
of the overall population of patients with gout in the United States of America. The severity 
of TFG is manifested by frequent acute attacks of disabling arthritis, chronic deforming joint 
disease, destructive masses of urate crystals (tophi), progressive physical disability, and poor 
health-related quality of life. Pegloticase (Krystexxa®; Savient Pharmaceuticals, Inc), a novel 
PEGylated urate oxidase (uricase) enzyme, has been resubmitted for US Food and Drug Admin-
istration approval. In a 6-month, placebo-controlled clinical trial, 8 mg of pegloticase for every 
2 weeks induced a lytic decrease of serum urate (sUr) concentrations, leading to dissolution of 
tophi in 40% of patients at final visit. However, 58% were nonresponders to the defined target 
sUr of 0.36 mmol/L (80% were nonresponders during months 3 and 6), possibly due to anti-
body formation. Also, 26%–31% experienced infusion reactions (IRs) and 77% suffered from 
gout flares. Although long-term data are awaited, an anti-inflammatory strategy, eg, based on 
glucocorticosteroids, is needed to prevent pegloticase antibody formation leading to IRs and 
diminished or shortened efficacy, and might also prevent gout flares. According to the current 
clinical data, pegloticase might have an important role as a (bridging) treatment in sUr-responsive 
patients for tophi clearance in severe chronic refractory gout.
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Introduction
Gout is the collective name for several clinical disorders that are characterized by 
dysmetabolism resulting in the formation and deposition of monosodium urate (MSU) 
crystals. The condition is associated with the recurrent episodes of acute joint pain 
due to the deposition of MSU crystals in the synovial fluid. In addition to these effects 
observed in the joints, skin or subcutaneous tissues and kidneys may also be affected 
by tophaceous deposits, cellulitis, urate nephropathy, and/or kidney stones. In most 
cases, no identifiable underlying cause of gout is present, but metabolic factors, such 
as reduced renal function, obesity, and the use of diuretics or salicylates, are usually 
present that may contribute to accumulation of urate (uric acid) in the body. Hyperuri-
cemia may exist for several years to decades before the first symptoms of gout attacks 
appear, and therefore, it is a disease associated and correlated with aging.
Gout is one of the most common inflammatory manifestations of arthritis; how-
ever, in general, it appears to be poorly managed.1,2 Partly, this is due to an absence 
of adequate treatment strategies and guidelines. In 2006, the European League against 
Rheumatism (EULAR) published the first international recommendations for the diag-
nosis and treatment of gout.3,4 The development of these EULAR and British Society 
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for Rheumatology guidelines coincided with the improved 
professional and patient education and the urge for improved 
professional performance.3–5 Until recently, allopurinol was 
the only antihyperuricemic drug with availability worldwide 
(Table 1). Two uricosurics with barriers regarding availability 
(benzbromarone and probenecid) have been available for 
years, but their exact place in the treatment strategy is not 
clear. In 2008 and 2009, respectively, European Medicines 
Agency and the US Food and Drug Administration (FDA) 
approved febuxostat (a selective nonpurine xanthine oxidase 
inhibitor) for the treatment of gout, thereby making a new 
treatment option available.6,7 A new uricosuric in clinical 
development, RDEA594, was presented in 2010.8
Pegloticase (Krystexxa®; Savient Pharmaceuticals, Inc., 
NJ), also known as Puricase® (Duke University and Mountain 
View Pharmaceuticals, Inc., Menlo Park, CA) or polyethylene 
glycol (PEG)-uricase, has been accepted for FDA resubmis-
sion in 2010 for the treatment of patients with conventional 
therapy refractory gout (CRG).9,10 In 2009, it was not approved 
for treatment-failure gout (TFG) because of manufacturing 
issues.11,12 The agency also wanted more communication with 
prescribing doctors about safety and monitoring. Although 
the definition of TFG and CRG differs slightly, this review 
will use TFG as the indication used initially. Pegloticase was 
granted orphan drug designation by the FDA in 2001. In the 
following topics, a review is given on pegloticase and its place 
in current treatment strategy.
Antihyperuricemic treatment
Antihyperuricemic maintenance therapy is indicated when 
recurrent gout attacks (.2/y) or tophi are presented by the 
patients.4,5,13 The treatment goal according to serum urate 
levels should be to achieve a sufficient negative urate mass 
balance to reverse the urate accumulation in the body. It is 
known from observational data that prevention of recur-
rent attacks and dissolution of tophi depend on the serum 
urate level that is achieved, preferably below 0.30 mmol/L 
(5 mg/dL).14–19 The rate of resorption of tophi is propor-
tional to the lowering of serum urate achieved.18 It may take 
years of chronic exposure to conventional urate-lowering 
agents in order to completely dissolve tophi. In fact, com-
plete resolution of tophi has never been demonstrated in a 
randomized controlled trial for any of the approved urate-
lowering agents.
In clinical practice, attainment of target urate levels is 
often difficult worldwide because of the limited efficacy, 
tolerability, and availability of current antihyperuricemic 
drugs.20,21 Some guidelines have set the serum urate target 
at 0.36 mmol/L (6 mg/dL), but this may be adequate only 
for long-term treatment after initial “debulking” in patients 
with progressive disease.4
The most commonly used urate-lowering drug is 
allopurinol. However, its effectiveness is limited by a 
number of issues, including the need to use lower doses in 
patients with renal insufficiency, failure to lower serum uric 
acid levels sufficiently due to subtherapeutic dosing, and 
an adverse event (AE) profile that includes gastrointesti-
nal, hepatic, renal, hematological, and skin toxicities that 
occur in an approximately 20% of patients who take this 
drug.22–29 Importantly, hypersensitivity reactions occur in 
2%–4% of patients that in some instances have been fatal.30 
It is estimated that approximately 5% of patients are forced 
Table 1 Antihyperuricemic drugs in gout
Drug Action: indication Daily dose: standard Characteristics
Allopurinol orally XOi: all 100–900 mg: 300 mg Dosage adjustment to 
renal function
Benzbromarone orally Urate transporter: low 
excretor, subject to 
intolerance or allergy  
to allopurinol
50–200 mg: 100 mg Poor efficacy in severe 
renal function impairment
Febuxostat orally XOi: all, particularly  
in Allo intolerance
40–120 mg: 80 mg No dosage adjustment in 
renal impairment
Probenecid orally Urate transporter: low 
excretor
500–2,000 mg: 1,000 mg Poor efficacy in moderate 
to severe renal function
Rasburicase iv UrO: lytic effect  
on tophi
Compassionate use: eg, 
0.2 mg/kg in 60 min; 
infusion on d 1, then 1x 
per wk; (+methylprednisolone 
100 mg iv)
Biological
Pegloticase iv UrO: chronic 
refractory gout
8 mg every 2–4 wk Biological
Abbreviations: XOi, xanthine oxidase inhibitor; iv, intravenous; UrO, urate oxidase.
Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
545
Review of pegloticase
to  discontinue allopurinol therapy due to the development 
of an AE.  Febuxostat, which was approved recently and 
does not require dose adjustment in mild to moderate renal 
impairment, may provide a therapeutic alternative for patients 
unable to tolerate allopurinol.7
Special considerations when 
antihyperuricemic treatment is used
Antihyperuricemic drugs might provoke arthritis or induce 
an attack of gout because of urate mobilization. For safety 
reasons, antihyperuricemic therapy should be given only 
after the gout attack has subsided, preferably with inflam-
matory protection (eg, low-dose colchicine, nonsteroidal 
anti-inflammatory drugs, or glucocorticosteroids), which 
should be initiated several days to two weeks earlier and 
given for a period of 2–3 months usually.4,31 With normal 
renal function, administration of allopurinol, probenecid, 
and benzbromarone could be started, respectively, at doses 
of 100 mg once daily, 250 mg twice daily, and 100 mg once 
daily (use of benzbromarone is not approved in the United 
States) and could be titrated every 2 weeks to standard 
dosage if tolerated. After 6–8 weeks, the efficacy can be 
evaluated and dose can be increased if necessary (Table 2). 
Maintenance doses usually range as follows: allopurinol, 
200–600 mg once daily; benzbromarone, 100–200 mg once 
daily; and probenecid, 500–1,000 mg twice daily. In case 
of impaired renal function, allopurinol dosage should be 
started at 100 or 50 mg/d (depending on the renal function), 
evaluated after 6–8 weeks, and titrated carefully (with 100 
or 50 mg/d).
When a history of urolithiasis is present, adequate 
diuresis should be ensured and alkalization should be con-
sidered, especially if a uricosuric is prescribed and the 
urine of the patient is acidic (pH , 6.0). Compliance is 
also a special consideration when supervising gout patients, 
and it is crucial to explain the dosing schedule and any 
potential side effects to the patient in order to prevent early 
withdrawal.
TFG and chronic refractory gout
TFG is a severe outcome of progressive gout resulting from 
the intolerance to or refractoriness to available urate-lowering 
therapy to prevent urate crystal deposition by reducing and 
maintaining serum urate levels in a subsaturating range. TFG 
is characterized clinically by painful arthritis and chronic 
arthropathy, destructive tophi, impaired quality of life, 
and chronic disability. Hyperuricemia and gout are often 
accompanied by significant medical comorbidities,  including 
 cardiovascular disease, hypertension,  hyperlipidemia, 
diabetes mellitus, chronic kidney disease, and obesity. These 
associated disorders are especially frequent among patients 
with TFG. The combination of severe gout and a high bur-
den of cardiovascular and metabolic comorbidities, often 
requiring polypharmacy, makes TFG exceptionally difficult 
to manage.11,32
TFG affects approximately 50,000 patients or about 
1% of the overall population of patients with gout in the 
United States.11 However, the prevalence may decrease with 
the availability of new (oral) antihyperuricemic drugs like 
febuxostat. The severity of TFG is manifested by frequent 
acute attacks of disabling arthritis, chronic deforming 
joint disease, destructive masses of urate crystals (tophi), 
progressive physical disability, and poor health-related 
quality of life. Several case reports describe successful 
(off-label) use of rasburicase in TFG.33–39 However, its use 
in gout is compromised: first, by the risk of immunologic 
Table 2 Suggested, current experience-based strategy for 
initiation of antihyperuricemic therapy6
1. Confirmation of diagnosis: detect urate crystals by means  
of polarization microscopy
2. Two or more gout flares per year or tophi/joint destruction due  
to gout attacks
3. Therapeutic advicea: allopurinol 100–300 mg/db
 allopurinol intolerance: consider febuxostat
4. Laboratory monitoring of the effectiveness at 6–8 wkc:
 sUr , 0.30 mmol/L, then continue allopurinol
  sUr . 0.30–0.36 mmol/L, but no further attacks (without 
colchicine/NSAiD/corticosteroids), then continue allopurinol
  sUr . 0.30 mmol/L plus gout attacks/persistent tophi and  
uUr . 1.5 mmol/24 h, go to 5
  sUr . 0.30 mmol/L plus gout attacks/persistent tophi with  
uUr , 1.5 mmol/24 h, go to 6
5. Therapeutic advice: increase allopurinol (eg, +100 mg/d or double the 
dose); then go to 4
Allopurinol inefficacy at maximum dosage (corrected for renal 
function): consider febuxostat
6. Therapeutic advice: add uricosuricum, eg, benzbromarone 100 mg/d 
or probenecid 500 mg twice daily; then go to 4
7. Laboratory monitoring of the effectiveness of sUr and  
uUr (possibly pHd) after 6 mo: see 5
8. Note: when trying to clear tophi, target value is  sUr , 0.30 mmol/L. 
Consider pegloticase when target value cannot be reached with 
conventional oral drugs or for more rapid debulkment in severe 
bulky disease
Notes: aSubject to motivation and tolerance by patient; bSubject to calculated creatinine 
clearance (cCC) . 50 mL/min, if cCC , 50 mL/min, then only increase allopurinol 
with 100 mg/day. Serum oxipurinol concentrations might be measured in patients 
with renal insufficiency; cTarget value for sUr # 0.36 mmol/L might be sufficient when 
there are no further gout attacks despite withdrawing colchicine/NSAiD, otherwise 
lower target value of 0.30 mmol/L; dif experiencing kidney stones or uUr . 6.0 mmol/ 
24 hours and pH , 7.0 consider alkalizing with sodium bicarbonate.
Abbreviations: sUr, serum urate; NSAID, nonsteroidal anti-inflammatory drug; 
uUr, 24-hour excretion of urate in urine.
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reactions; second, by its short half-life (18 hours) that 
demands an infusion every 1–2 weeks according to serum 
urate levels for optimal treatment efficacy; and third, by the 
lack of clinical experience and a dosing scheme consensus 
for gout.40 Terkeltaub40 has proposed to use uricase-based 
therapy in severe tophaceous gout as bridging therapy for 
rapid debulking of urate, whereafter a less rigorous regi-
men might be sufficient, while maintaining a negative urate 
balance.
Pharmacology
Pegloticase is intended for use in TFG at a dose of 8 mg (of 
uricase protein) by intravenous infusion every 2 weeks. The 
active substance is a genetically engineered, recombinant, 
PEG-conjugated mammalian (porcine-like) uricase enzyme. 
It metabolizes uric acid into soluble allantoin for excretion 
by the kidney, with hydrogen peroxide and carbon dioxide 
as oxidative byproducts. It is PEGylated in order to lengthen 
the circulating half-life of the enzymatically active uricase 
moiety and to lessen the immunogenicity in long-term use. 
Because urate, the substrate of this enzyme, is small in size, 
it is able to diffuse through a web of polymer molecules to 
reach active sites. This concept for uricase has already been 
described and clinically demonstrated in 1981.41,42
A Phase I study investigated the pharmacokinetics, phar-
macodynamics, and safety of pegloticase by single subcuta-
neous injection in 13 subjects with TFG.43 It appeared that in 
5 of 13 patients, the half-life of pegloticase was significantly 
lower than in the rest of the group and no measurable activity 
was present after 10 days, whereas in the other 8 patients, 
activity was still present after 21 days.43 The faster clearance 
in these 5 patients was demonstrated to be related to the pres-
ence of IgM and IgG antibodies against pegloticase.
In a second Phase I study (n = 24), pegloticase was given 
as a single dose intravenously. The most efficacious dosage 
for reducing serum urate (sUr) were 4, 8, and 12 mg. The 
volume of distribution ranged from 5.0 to 10 L, the t
1/2
 ranged 
from 163 to 332 hours, and C
max
 values ranged from 1.7 to 
36 mU/mol (1 U = 1 µmol urate oxidized per minute). It was 
also noted that the rate of terminal clearance was increased in 
patients in whom IgG was expressed to the pegloticase.44
Pegloticase in clinical trials
In a Phase II clinical trial of 12 weeks (n = 41), patients were 
divided into four cohorts and received pegloticase during 
the 12 weeks at a dosage of 4 or 8 mg for every 2 weeks or 
8 or 12 mg for every 4 weeks.45–47 These data demonstrate 
that patients treated with 8 mg of pegloticase for every 2 or 
4 weeks had a lytic, ie, very rapid and sustained reduction in 
plasma uric acid; 4 mg for every 2 weeks was not as effec-
tive, and 12 mg for every 4 weeks did not provide additional 
benefit compared with 8 mg for every 4 weeks. A majority of 
patients developed antibodies to pegloticase; infusion reac-
tions (IRs) appeared to be associated with the presence of an 
antibody response. The data also show that these patients can 
be categorized into two groups based upon their sUr values 
after repeated pegloticase treatment: 1) persistent responders 
(previously referred to as responders), who had a sustained 
reduction in sUr, and 2) transient responders (previously 
referred to as nonresponders), who initially had sUr values 
below 0.36 mmol/L but the values increased over time to 
above 0.36 mmol/L. Although all patients had a response 
after the first pegloticase administration, those patients who 
developed antibodies appeared to have transient respon-
siveness and a higher risk for IRs. Also, cases of patients 
experiencing profound improvements in their joint function 
and breakdown of existing gout tophi were reported during 
the 12-week trial.48
On the basis of the safety and efficacy results of the 
Phase II study, the pegloticase dose selected for advancement 
to Phase III registration studies was 8 mg administered 
intravenously (diluted to 250 mL) over 120 minutes every 
2 weeks or every 4 weeks.11,42
Two Phase III, 6-month, randomized, double-blind trials 
were performed in patients with TFG: Gout Outcome and Urate 
Therapy (GOUT1 and GOUT2).49,50 TFG was defined as fol-
lows: $3 flares in previous 18 months, $1 tophus, or prevalent 
gouty arthropathy; sUr $8.0 mg/dL; and contraindication to or 
self-reported failure to control sUr with maximum medically 
appropriate dose of allopurinol. In total, 212 subjects received 
(by randomization 2:2:1) 8 mg of pegloticase (of uricase 
protein) for every 2 weeks (n = 85) or every 4 weeks (n = 84) 
or received placebo (n = 43). Colchicine or nonsteroidal 
anti-inflammatory drugs were used for gout prophylaxis. IR 
prophylaxis consisted of oral fexofenadine and paracetamol 
and hydrocortisone 200 mg intravenously before infusion. The 
primary efficacy end point was the percentage of sUr respond-
ers, defined as the subjects with sUr , 0.36 mmol/L $ 80% 
of the time in months 3 and 6. Secondary end points assessed 
treatment effect on tophus size, gout flares, number of swollen 
and tender joints (TJs), quality of life (SF-36, physical com-
ponent summary score), and disability (health-related quality 
of life as determined by the Health Assessment Questionnaire 
Disability Index [HAQ-DI]).51,52 Primary end point data are 
reported as replicate analyses; secondary end point data were 
pooled for GOUT1 and GOUT2.
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Subjects, mean age 55 years, were mostly male (82%) 
and had high cardiovascular comorbidity rates. Plasma 
urate response was significantly higher in both pegloticase 
groups vs placebo group in both studies and ranged from 
35%–42% vs 0% (Table 3). Complete resolution of $1 
tophus occurred in 40% of pegloticase every-2-weeks patients 
(P = 0.002) and in 21% of pegloticase every-4-weeks patients 
(not significant vs placebo) vs 7% in placebo subjects; 
in 22%, tophus resolution occurred within 13 weeks.53–55 
SF-36, HAQ-DI, and TJs improved significantly in both peg-
loticase groups vs placebo group.56,57 Incidence and frequency 
of gout flare were significantly higher during months 1–3 in 
both pegloticase groups despite prophylaxis but were signifi-
cantly lower during months 4–6 in pegloticase every-2-weeks 
group (41%) vs placebo group (67%, P = 0.007). The most 
common AEs were flares (in 77% pegloticase every-2-weeks, 
83% pegloticase every-4-weeks, 81% placebo subjects) and 
IRs (in 26% pegloticase every-2-weeks, 41% pegloticase 
every-4-weeks, 5% placebo subjects). AE discontinuations 
were mostly due to IRs (19/34). Serious AEs, mostly flares 
and IRs, occurred in 24% pegloticase every-2-weeks, 23% 
pegloticase every-4-weeks, and 12% placebo subjects.
In conclusion, 42% and 35% of TFG subjects on peg-
loticase every-2-weeks and every-4-weeks, respectively, 
achieved the primary efficacy end point of sUr control. 
This was accompanied by significant improvement in 
clinical outcomes. Subjects who completed the GOUT1 
or GOUT2 trial were given the option to enter an open-
label extension trial under a separate protocol (GOUT3). 
In an update of the extension study (GOUT3), efficacy 
in reduction of sUr concentration and symptomatic end 
points were reported to be maintained with treatment 
extending up to 1 year.58
Table 3 summarizes the efficacy and tolerability results 
of pegloticase in randomized controlled trials, which were 
reviewed by the FDA and some recent review articles 
previously.11,59,60
Safety and tolerability
The FDA review of safety database for pegloticase identi-
fied concerns in three main areas: 1) a higher rate of serious 
cardiovascular events, 2) the occurrence of IRs and allergic 
reactions, and 3) immunogenicity of pegloticase with an 
adverse influence on efficacy and safety (Table 4).11 Deaths 
were seen in both study arms, in 4% in the pegloticase arm 
vs 1% in the placebo arm, but there were no significant 
statistical differences.
The higher rate of serious cardiovascular events was 
seen in both pegloticase treatment arms and demonstrated 
no  relation to dosage regimen. The cardiovascular events 
showed no particular pattern and included arrhythmias, 
ischemic events, and congestive heart failure. A consultation 
from the FDA Division of Cardiovascular and Renal Drug 
Products concluded that the distribution of cardiovascular 
deaths and cardiac severe AEs was not obviously unusual 
in view of the fact that it occurred in patients predisposed to 
such events and taking into account the unequal randomiza-
tion in the clinical trials.11
Table 3 Efficacy and tolerability of pegloticase in randomized controlled trials
Study Treatment, 
dosage
No. of 
patients
Duration sUr , 6 mg/dL 
(0.36 mmol/L)a
Gout flares Tophus dissolution 
(final visit)
Withdrawal due 
to ADR
Phase i43 4–24 mg sc 13 single dose – – – –
Phase i44 0.5–12 mg iv 24 single dose – – – –
Phase ii45,46 4 mg iv q2w 
8 mg iv q2w 
8 mg iv q4w 
12 mg iv q4w
41 3 mo 4/7 (57.1%) 
7/8 (87.5%) 
7/13 (53.8%) 
8/13 (61, 5%)
86% 
63% 
92% 
100%
Not available 
Case reports48
15 (37%)
GOUT 1 and 
GOUT 249,50
8 mg iv q2w 43 + 42 26 wk 20/43 (46.5%) 
(P , 0.001)b and 
16/42 (38.1%) 
(P , 0.001)b
mo 1–3:  
77%; mo 
4–6: 41% 
(P = 0.007)b
21/52 (40.4%) 1 (2%)
8 mg iv q4w 41 + 43 8/41 (19.5%) 
(P = 0.044)b and 
21/43 (48.8%) 
(P , 0.001)b
mo 1–3: 81%;  
mo 4–6: 57%
11/52 (21.2%) 16 (19%)
Placebo 20 + 23 0/20 (0%) and  
0/23 (0%)
mo 1–3: 54%;  
mo 4–6: 67%
2/29 (6.9%) 17 (20%)
Notes: aProportion of subjects maintaining a PUA concentration ,6 mg/dL for at least 80% of the time during the treatment period (Phase ii) or during the months 3 and 6 
(Phase iii); bPegloticase vs placebo.
Abbreviations: ADR, adverse drug reactions; PAU, plasma uric acid.
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A higher proportion of patients experienced serious 
AEs in the pegloticase every-4-week (23%) and pegloticase 
every-2-week (24%) treatment groups as compared with 
placebo-treated patients (12%) due to the high rate of IRs 
seen in the pegloticase every-4-week (41%) and pegloticase 
every-2-week (26%) groups. A higher proportion of IRs that 
were experienced by the patients in the pegloticase every-
4-week group (36%) was of moderate to severe intensity 
as compared with the pegloticase every-2-week group 
(18%). The occurrence of IRs peaked with the administra-
tion of dose 3 or 4 of pegloticase and declined thereafter. 
Pegloticase was shown to be immunogenic with 88% of 
patients in the pegloticase every-2-week group and 89% of 
patients in the pegloticase every-4-week group seroconvert-
ing to antibody positivity over the course of these studies. 
The magnitude of positive antibody titers to pegloticase 
was associated with a higher rate of IRs and a decrease in 
urate-lowering effects of therapy.61 Routine sUr monitoring 
might be used to prospectively identify patients receiving 
pegloticase who may no longer benefit from treatment and 
are at greater risk for IRs.62 A next generation, less immu-
nogenic form of PEG-uricase might be developed in which 
uricase will be coupled to PEG lacking a methoxyl or other 
alkoxyl group at the terminus remote from the protein-
coupling function.9
Because of the formation of hydroxen peroxide by 
uricase, pegloticase therapy may be complicated in patients 
with deficiencies of glucose-6-phosphate dehydrogenase or 
catalase.63,64
In conclusion, a strategy on prevention of immunologic 
responses is warranted, eg, by prescribing anti-inflammatory 
regimen. The same regimen may also be very useful for the pre-
vention of gout flares because of the mobilization of urate due to 
the rapid urate metabolism in the circulation by pegloticase.
Summary
In 6-month, placebo-controlled clinical trials, 8 mg of pegloti-
case for every 2 weeks induces a lytic decrease of sUr, leading 
to dissolution of tophi in 40% of patients at final visit (45% in 
subjects treated for 25 weeks). The velocity of tophus dissolution 
in responders to pegloticase seems faster than combination treat-
ment of allopurinol and benzbromarone (19.6 ± 9.1 months), 
which may be clinically significant. However, 58% are non-
responders to the defined target sUr of 0.36 mmol/L (for 80% 
of the time during months 3 and 6), which is correlated with 
antibody formation to pegloticase and IRs. Moreover, 26%–31% 
of subjects experienced IRs and 77% suffered from gout flares 
(mostly in first 3 months). Although long-term data are awaited, 
an anti-immunologic or anti-inflammatory strategy is needed to 
prevent antipegloticase antibody formation, which is associated 
with IRs and diminished or shortened efficacy, and the strategy 
might also prevent gout flares induced by urate mobilization at 
the same time.
A good news for patients who cannot be treated with 
classic antihyperuricemic drugs is the recent availability of 
febuxostat and the development of other antihyperuricemic 
drugs that might be less efficacious than pegloticase but 
may well have a better benefit or risk balance in the long 
Table 4 Summary of treatment-emergent AEs including IRs and gout flares reported11
Safety 
characteristics 
(No.)
GOUT 1 and 2 GOUT 3
Placebo 
(N = 43)
Pegloticase q2 wk 
(N = 85)
Pegloticase q4 wk 
(N = 84)
Pegloticase q2 wk 
(N = 85)
Pegloticase q4 wk 
(N = 84)
Adverse events (Aes) 370 693 870 1,044 1,411
Subjects with Aes 41 (95%) 80 (94%) 84 (100%) 83 (98%) 84 (100%)
Subjects with serious  
Aes (SAe)
5 (12%) 20 (24%) 19 (23%) 24 (28%) 27 (32%)
Subjects with 
infections
22 (51%) 30 (35%) 40 (48%) 41 (48%) 54 (64%)
Subjects with serious 
infections
4 (9%) 3 (4%) 5 (6%) 3 (4%) 7 (8%)
Subjects with 
malignancy
1 (2%) 0 (0%) 1 (1%) 0 (0%) 1 (1%)
Subjects with infusion 
reactions (iR)
2 (5%) 22 (26%) 34 (41%) 26 (31%) 38 (45%)
Subjects who 
discontinued 
due to Aes
1 (2%) 16 (19%) 17 (20%) 18 (21%) 21 (25%)
Deaths 1 (2%) 3 (4%) 1 (1%) 0 (0%) 2 (2%)
Note: except for the “number of Aes”, subjects are counted only once in each row.
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term. Nevertheless, according to the current clinical data, 
pegloticase might have an important role as bridging treat-
ment, eg, for 6 months in sUr responsive patients for rapid 
urate debulking in severe (treatment refractory) gout. After 
successful dissolution of tophi, a less rigorous regimen pos-
sibly with new drugs like febuxostat might be sufficient while 
maintaining a negative urate mass balance.
Pegloticase has been accepted for resubmission for 
approval by the FDA and may provide an important, novel 
option in patients with chronic refractory gout.
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